Ligand Pharmaceuticals (LGND) Free Cash Flow Growth (5y) (2015 - 2026)

Ligand Pharmaceuticals (LGND) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Ligand Pharmaceuticals 5.92 Bn 5.14 Bn 48.45 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 45.82%
Dec 31, 2025 132.75%
Sep 30, 2025 0.69%
Jun 30, 2025 -7.90%
Mar 31, 2025 -28.63%
Dec 31, 2024 36.89%
Sep 30, 2024 51.00%
Jun 30, 2024 21.64%
Mar 31, 2024 -16.16%
Dec 31, 2023 -18.83%
Sep 30, 2023 -28.50%
Jun 30, 2023 -52.39%
Mar 31, 2023 -12.29%
Dec 31, 2022 3.48%
Sep 30, 2022 -4.45%
Jun 30, 2022 4.34%
Mar 31, 2022 19.76%
Dec 31, 2021 7.09%
Sep 30, 2021 4.42%
Jun 30, 2021 14.64%